Clinical Trials

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC-T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)

Interim results from the Phase I TACTIC-02 study demonstrated a favorable safety profile for TAC100-HER2 treatment, as well as early signals of clinical activity in patients with gastric and esophageal tumors, including impressive disease control rates and partial responses in heavily pre-treated patients. TAC100-HER2 is being investigated for the treatment of HER2-positive gastric and esophageal tumors in a Phase 2 trial, which is currently recruiting new patients.

Read the Complete Clinical Trial Brief at ClinicalTrials.gov

A Phase I/II Trial Investigating Safety and Efficacy of Autologous TAC-T Cells Targeting HER2 in Relapsed or Refractory Solid Tumors (TACTIC-2)

Dose Escalation Phase - Combination with Pembrolizumab

Indications:
HER2+ gastric and gastroesophageal adenocarcinoma (2+, 3+ HER2 expression)

Status:
Now recruiting

Planned Locations:

  • Dana Farber Cancer Institute in Boston, Massachusetts
  • University of Chicago Comprehensive Cancer Center in Chicago, Illinois
  • Lurie Cancer Center, Northwestern University in Chicago, Illinois
  • MD Anderson Cancer Center in Houston, Texas
  • Roswell Park Comprehensive Cancer Center in Buffalo, New York
  • Memorial Sloan Kettering Cancer Center in New York, New York
  • University of Cincinnati Cancer Center in Cincinnati, Ohio
  • Sidney Kimmel Cancer Center, Thomas Jefferson University in Philadelphia, Pennsylvania
  • Princess Margaret Cancer Center in Toronto, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Quebec, Canada

Dose Expansion Phase - Monotherapy

Indication Cohorts:
HER2+ gastric and esophageal adenocarcinoma (2+, 3+ HER2 expression)

Status:
Now recruiting

Planned Locations:

  • Dana Farber Cancer Institute in Boston, Massachusetts
  • University of Chicago Comprehensive Cancer Center in Chicago, Illinois
  • Lurie Cancer Center, Northwestern University in Chicago, Illinois
  • MD Anderson Cancer Center in Houston, Texas
  • Roswell Park Comprehensive Cancer Center in Buffalo, New York
  • Memorial Sloan Kettering Cancer Center in New York, New York
  • University of Cincinnati Cancer Center in Cincinnati, Ohio
  • Sidney Kimmel Cancer Center, Thomas Jefferson University in Philadelphia, Pennsylvania
  • Princess Margaret Cancer Center in Toronto, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM) in Montreal, Quebec, Canada

Contact us for more information on our trials.